Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E6.89 EPS (ttm)11.35 Insider Own0.50% Shs Outstand1.32B Perf Week-3.40%
Market Cap103.56B Forward P/E6.69 EPS next Y11.69 Insider Trans-16.96% Shs Float1.31B Perf Month-1.64%
Income16.35B PEG86.07 EPS next Q2.88 Inst Own80.50% Short Float1.33% Perf Quarter-9.71%
Sales32.37B P/S3.20 EPS this Y62.00% Inst Trans-2.77% Short Ratio1.70 Perf Half Y-11.93%
Book/sh11.64 P/B6.72 EPS next Y-0.80% ROA32.70% Target Price105.65 Perf Year-26.11%
Cash/sh6.61 P/C11.83 EPS next 5Y0.08% ROE100.80% 52W Range77.63 - 111.65 Perf YTD-21.94%
Dividend1.88 P/FCF7.12 EPS past 5Y48.30% ROI45.90% 52W High-30.21% Beta1.06
Dividend %2.41% Quick Ratio1.60 Sales past 5Y32.60% Gross Margin87.10% 52W Low0.37% ATR1.49
Employees8000 Current Ratio1.80 Sales Q/Q-5.70% Oper. Margin63.00% RSI (14)35.11 Volatility1.86% 1.52%
OptionableYes Debt/Eq1.42 EPS Q/Q-11.50% Profit Margin50.50% Rel Volume0.90 Prev Close78.17
ShortableYes LT Debt/Eq1.38 EarningsJul 25 AMC Payout15.20% Avg Volume10.24M Price77.92
Recom2.20 SMA20-2.55% SMA50-5.42% SMA200-13.27% Volume9,169,211 Change-0.32%
Jul-29-16Downgrade Argus Buy → Hold
Jul-26-16Reiterated RBC Capital Mkts Outperform $120 → $105
Jul-26-16Downgrade Needham Buy → Hold
Jun-01-16Initiated Gabelli & Co Buy $109
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Feb-12-16Reiterated Maxim Group Buy $137 → $115
Feb-03-16Reiterated RBC Capital Mkts Outperform $130 → $120
Feb-03-16Reiterated Piper Jaffray Overweight $134 → $114
Feb-03-16Reiterated Oppenheimer Outperform $124 → $120
Feb-03-16Reiterated Barclays Overweight $130 → $115
Feb-03-16Initiated Standpoint Research Buy $110
Jan-20-16Initiated Credit Suisse Outperform $125
Jan-15-16Upgrade BofA/Merrill Underperform → Neutral $107
Oct-28-15Reiterated Maxim Group Buy $129 → $137
Oct-20-15Reiterated Oppenheimer Outperform $120 → $124
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-09-15Initiated Jefferies Hold
Aug-30-16 03:06PM  University of Minnesota sues Gilead over $20 billion Hepatitis C drug business at bizjournals.com
08:02AM  2 Clinical-Stage Biotech Stocks to Buy at Motley Fool
Aug-29-16 04:04PM  Gilead, Ceasars in Mondays 52-Week Low Club at 24/7 Wall St.
02:16PM  Gilead Sciences (GILD) Stock Down, Piper Jaffray 'Doubts' HIV Competitors
01:34PM  Gilead Sciences: Don't Expect Perfection at Barrons.com
01:28PM  Gilead Was Smart to Let Medivation Slip Through its Fingers
12:53PM  Five Healthcare Stocks Hedge Funds Like at Insider Monkey
12:09AM  Glaxo Bets It Can Shake Up HIV Treatment at The Wall Street Journal
Aug-28-16 02:40PM  [$$] Glaxo Bets It Can Shake Up HIV Treatment at The Wall Street Journal
07:24AM  Billionaire George Soros' Fund Dumped These 3 Biotech Holdings. Should You? at Motley Fool
Aug-27-16 06:36PM  Here Are All The Big Biotech Mergers In 2016
Aug-26-16 12:34PM  Gilead (GILD) Stock Lower, Citigroup: Hepatitis C Drug Sales Look Weak
12:30PM  9 Stocks to Buy That Will Sprint Past Everything Else at Kiplinger
10:05AM  Gilead Sciences: Hepatitis C Still Disappointing? at Barrons.com
07:41AM  3 Top Stocks to Buy for Your Children at Motley Fool
Aug-25-16 02:20PM  Biotech building on the Peninsula bounces back and it needs space to grow at bizjournals.com
09:01AM  3 Reasons Gilead Sciences Inc. Stock Could Fall at Motley Fool
08:40AM  Short Sellers Increase Bets in Major Biotechs at 24/7 Wall St.
Aug-24-16 04:40PM  Gilead Sciences Shares Slide on Leerink Price Target Cut at TheStreet
02:09PM  Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
11:24AM  Gilead (GILD) Price Target Cut Amid Weak Outlook for HIV Drug Sales
09:49AM  Gilead Sciences: It's Not Just Hepatitis C That's Disappointing at Barrons.com
08:02AM  Why You Should (and Shouldn't) Buy Gilead Sciences, Inc. at Motley Fool
Aug-23-16 04:19PM  GILEAD SCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
02:39PM  Pfizer & Medivation: A Big Win Like Gilead-Pharmasset or a Big Bust Like Bristol-Inhibitex? at Barrons.com
10:02AM  Gilead (GILD) Truvada Gets EU Approval for Label Expansion
09:44AM  4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss at Barrons.com
08:55AM  Kelly A. Kramer Joins Gilead Sciences Board of Directors Business Wire
07:25AM  3 Cheap Healthcare Stocks Paying Dividends Now at Motley Fool
12:09AM  [$$] Pfizers Medivation Deal Latest in Long Line of Similar Acquisitions at The Wall Street Journal
Aug-22-16 01:11PM  Here's Why a Gilead Stock Split Is Unlikely at Motley Fool
12:51PM  Gilead Sciences (GILD) Stock Up on HIV Drug Approval
12:22PM  [$$] Pfizer's Medivation Deal Latest in Long Line of Similar Acquisitions at The Wall Street Journal
11:49AM  European Commission Grants Marketing Authorization for Gileads Once-Daily Truvada® For Reducing the Risk of Sexually Acquired HIV-1 Business Wire
10:06AM  Pfizer buys Medivation $14 billion cash
09:53AM  Pfizer Will Buy Cancer Drugmaker Medivation For $14 Billion
Aug-21-16 10:00AM  Here's why prescription drug costs are on the rise at CNBC
09:50AM  Top Undervalued Stocks to Buy in 2016 at Motley Fool
Aug-20-16 09:34AM  7 Battered Biotech Stocks to Buy at Kiplinger
Aug-19-16 12:39PM  Biotech Stocks: Trouble Ahead, Trouble Behind? at Barrons.com
11:45AM  Gilead Sciences (GILD) Stock Up, Piper Jaffray: Splitting Is 'Poor Idea'
10:05AM  Break Up Gilead Sciences? Not So Fast at Barrons.com
07:00AM  Quality at a Low Cost at Morningstar
Aug-18-16 02:08PM  Gilead May Be Better Off Splitting Itself in Two, Analysts Say
12:50PM  How Much Medivation Can Really Fetch in a Buyout at 24/7 Wall St.
Aug-17-16 06:34PM  These stocks could soar 50% over the next year, experts say at CNBC
04:32PM  Merck Among Drug Giants Looking To Buy Medivation, Says Report
03:41PM  Which stocks will soar 50% over the next year?
03:32PM  Gilead: Why A Split Up Is Much Needed For Turnaround Growth?
03:24PM  Gilead Sciences: Still Dominating Hepatitis C But at Barrons.com
02:26PM  BetterInvesting Top 100 Grew 13.3 Percent Annually for 5 Years Through July PR Newswire
01:03PM  [$$] Gilead: breaking the fever at Financial Times
11:04AM  What Do Analysts Estimate for Merck?
08:20AM  3 Cheap Stocks for Rookie Investors to Start With at Motley Fool
Aug-16-16 12:08PM  The Least Popular Stocks This 13F Season
11:24AM  Gilead (GILD) Stock Lower, Piper Jaffray: Little Required to 'Driver Shares Higher'
10:37AM  Gilead Sciences: Not Much Has to Go Right to Make It a Winner at Barrons.com
08:18AM  4 Top Biotech Stocks That Can Be Purchased on the Cheap This Summer at Motley Fool
Aug-15-16 04:56PM  Buffett's Berkshire Ups Apple Stake As Others Sell iPhone Maker, Netflix
02:55PM  Omega Advisors: Exits Apple, Slashes Chimera, Adds Citigroup at Barrons.com
Aug-14-16 08:44AM  These 3 Hated Dividend Stocks Look Like Buys at Motley Fool
Aug-13-16 02:06PM  Could Gilead Sciences Face an Unexpected $10 Billion Tax Bill? at Motley Fool
Aug-12-16 04:08PM  How Will Gilead (GILD) Stock React to Hepatitis-C Drug Prescriptions?
03:58PM  Gilead Could Be Better off Splitting Drug Businesses -- RBC Capital at TheStreet
03:16PM  Gilead Sciences: The Pressure is (Still) On at Barrons.com
01:09PM  Analysts Recommendations for Celgene and Its Peers in 2016
01:09PM  How Do Celgenes Valuation Multiples Compare to Its Peers?
01:04PM  GILEAD SCIENCES INC Financials
01:03PM  Should Gilead Split in Two?
11:31AM  Gilead Faces Blow as HCV Market Heads for Secular Decline
09:14AM  This beaten-down biotech stock is a cure for your portfolio at MarketWatch
06:30AM  Analysts: Gilead Should Divide Itself and Conquer
12:12AM  [$$] Biotechs Resurgence May Cost Big Pharma at The Wall Street Journal
Aug-11-16 08:38PM  Gilead to get attorney fees in hepatitis C patent fight with Merck Reuters
12:28PM  Valeant sinks on criminal probe
11:37AM  [$$] Biotech's Resurgence May Cost Big Pharma at The Wall Street Journal
08:20AM  Why Jefferies Sees 3 Big Biotechs Having Key Upside Catalysts Coming at 24/7 Wall St.
Aug-10-16 03:39PM  Where's The New Nifty Fifty? at Forbes
01:39PM  Gilead (GILD) Stock Slumps, Leerink: Drug Success Overshadowed By Sales Decline
12:54PM  Gilead Sciences: Going, Going at Barrons.com
08:50AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
Aug-09-16 10:49AM  Biotech Stocks: Blame Gilead? at Barrons.com
Aug-08-16 01:46PM  How Did Regenerons Revenue and Earnings Look in 2Q16?
Aug-06-16 08:00AM  Top Insider Trades: Amazon's Bezos; Northrop, Southwest, Gilead CEOs
Aug-05-16 04:15PM  GILEAD SCIENCES INC Files SEC form 10-Q, Quarterly Report
06:48AM  Ligand (LGND) Q2 Earnings Decline Y/Y, Maintains View
Aug-04-16 06:42PM  Healthcare Dividend Growth Stocks: Part 1
10:33AM  Drug Stocks' Earnings to Watch on Aug 5: PETX, DVAX & More
10:00AM  Amid Biotech Rally, Investors Show Jitters
Aug-03-16 12:30PM  Time to buy biotech?
09:04AM  Gilead Sciences Continues to Focus on Improving Care for HCV Patients
08:07AM  Pro: Biogen did not put 'for sale' sign out
Aug-02-16 05:15PM  Biogen: Deal or no deal?
05:00PM  Biogen surges on takeover talk. 4 Trades
12:33PM  [$$] Health service chiefs to challenge HIV drug ruling at Financial Times
10:30AM  Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More
09:04AM  These Concerns Affected Gileads Change in Full-Year Guidance
05:58AM  UK court says state health system can fund preventative HIV drug Reuters
Aug-01-16 07:30PM  Express Scripts says Valeant, Lilly, Bristol drugs to lack coverage Reuters
05:49PM  Will the biotech rally will continue?
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company's products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lofton Kevin EDirectorAug 24Sale81.973,500286,8990Aug 25 05:05 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise39.132,00078,25564,305Aug 03 04:48 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise16.40100,0001,639,5004,119,727Aug 03 04:51 PM
MILLIGAN JOHN FPresident and CEOAug 01Option Exercise20.7470,0001,451,8001,128,963Aug 03 04:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale80.50100,0008,049,7854,019,727Aug 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Sale79.812,000159,62062,305Aug 03 04:48 PM
MILLIGAN JOHN FPresident and CEOAug 01Sale70.9470,0004,965,5901,058,963Aug 03 04:53 PM
Carter Paul RutherfordEVP Commercial OpsJul 31Option Exercise0.002,500063,622Aug 02 04:43 PM
MILLIGAN JOHN FPresident and CEOJul 05Option Exercise16.40112,0001,836,2401,170,963Jul 07 02:50 PM
MILLIGAN JOHN FPresident and CEOJul 05Sale84.33112,0009,444,9211,058,963Jul 07 02:50 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise24.912,00049,81063,122Jul 06 01:26 PM
MARTIN JOHN CExecutive ChairmanJul 01Option Exercise16.40100,0001,639,5004,119,727Jul 06 01:28 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Sale83.122,000166,25061,122Jul 06 01:26 PM
MARTIN JOHN CExecutive ChairmanJul 01Sale84.73100,0008,472,5234,019,727Jul 06 01:28 PM
MILLIGAN JOHN FPresident and CEOJun 06Option Exercise16.40112,0001,836,2401,170,963Jun 08 06:59 PM
MILLIGAN JOHN FPresident and CEOJun 06Sale86.94112,0009,736,7791,058,963Jun 08 06:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Option Exercise24.912,00049,81063,122Jun 03 04:46 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise16.40100,0001,639,5004,119,727Jun 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Sale87.022,000174,04061,122Jun 03 04:46 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale86.72100,0008,671,9504,019,727Jun 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Option Exercise33.8857,0921,934,021118,214Jun 02 04:35 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Sale86.8557,0924,958,60061,122Jun 02 04:35 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Option Exercise39.132,00078,25563,122May 04 04:23 PM
MARTIN JOHN CExecutive ChairmanMay 02Option Exercise16.40100,0001,639,5004,119,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Option Exercise16.40112,0001,836,2401,170,963May 04 02:49 PM
MARTIN JOHN CExecutive ChairmanMay 02Sale87.82100,0008,781,6944,019,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Sale87.71112,0009,823,9541,058,963May 04 02:49 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Sale88.722,000177,44861,122May 04 04:23 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Option Exercise26.9935,874968,239177,964Apr 21 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Sale100.0140,0004,000,574137,964Apr 21 01:28 PM
MILLIGAN JOHN FPresident and CEOApr 04Option Exercise16.40112,0001,836,2401,170,963Apr 05 07:30 PM
MILLIGAN JOHN FPresident and CEOApr 04Sale94.59112,00010,593,9041,058,963Apr 05 07:30 PM
MARTIN JOHN CExecutive ChairmanApr 01Option Exercise16.40100,0001,639,5004,119,727Apr 05 07:49 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise24.912,00049,81063,122Apr 05 06:36 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale91.342,000182,68061,122Apr 05 06:36 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale91.235,000456,158142,090Apr 05 07:45 PM
MARTIN JOHN CExecutive ChairmanApr 01Sale93.24100,0009,323,5074,019,727Apr 05 07:49 PM
Alton Gregg HEVP, Corp & Med AffairsMar 14Sale90.005,000450,000147,090Mar 15 07:31 PM
MARTIN JOHN CChairman and CEOMar 01Option Exercise16.40100,0001,639,5004,119,727Mar 03 02:47 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Option Exercise16.40112,0001,836,2401,170,963Mar 03 02:54 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Option Exercise24.912,00049,81063,122Mar 03 03:10 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Sale87.79112,0009,832,9951,058,963Mar 03 02:54 PM
MARTIN JOHN CChairman and CEOMar 01Sale88.58100,0008,857,8544,019,727Mar 03 02:47 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Sale87.902,000175,80061,122Mar 03 03:10 PM
Washington Robin LEVP, CFOFeb 16Sale90.726,250567,00084,688Feb 18 07:59 PM
MARTIN JOHN CChairman and CEOFeb 01Option Exercise16.40100,0001,639,5004,048,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Option Exercise39.142,00078,27150,783Feb 03 05:42 PM
MARTIN JOHN CChairman and CEOFeb 01Sale83.42100,0008,342,4753,948,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Sale82.322,000164,64048,783Feb 03 05:42 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Option Exercise25.762,00051,52650,783Jan 06 05:08 PM
MARTIN JOHN CChairman and CEOJan 04Option Exercise16.40100,0001,639,5004,048,066Jan 06 05:21 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Sale99.202,000198,40048,783Jan 06 05:08 PM
MARTIN JOHN CChairman and CEOJan 04Sale97.68100,0009,767,7083,948,066Jan 06 05:21 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Option Exercise21.9970,0001,539,562197,936Dec 17 03:40 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Sale102.4170,0007,168,741127,936Dec 17 03:40 PM
MILLIGAN JOHN FPresident and COODec 07Option Exercise14.50100,0001,450,2501,129,108Dec 09 02:14 PM
MILLIGAN JOHN FPresident and COODec 07Sale103.18100,00010,317,9771,029,108Dec 09 02:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.3010,000242,950141,422Dec 03 01:57 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise26.992,00053,98050,783Dec 03 01:56 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise14.50150,0002,175,3754,098,066Dec 03 01:57 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale106.382,000212,76048,783Dec 03 01:56 PM
MARTIN JOHN CChairman and CEODec 01Sale105.82150,00015,873,4673,948,066Dec 03 01:57 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale106.0112,0001,272,159129,422Dec 03 01:57 PM
Cogan John FrancisDirectorNov 24Option Exercise20.7115,000310,57559,309Nov 25 02:21 PM
Cogan John FrancisDirectorNov 24Sale105.9515,0001,589,19044,309Nov 25 02:21 PM
Whitley Richard JamesDirectorNov 24Sale106.4816917,99530,719Nov 25 02:22 PM
Whitley Richard JamesDirectorNov 23Sale107.182,863306,84530,888Nov 25 02:22 PM
Whitley Richard JamesDirectorNov 20Sale106.995,514589,91733,751Nov 25 02:22 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 16Option Exercise23.7670,0001,662,850235,168Nov 18 12:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 16Sale102.6570,0007,185,419165,168Nov 18 12:32 PM
MILLIGAN JOHN FPresident and COONov 09Option Exercise14.50100,0001,450,2501,129,108Nov 12 01:01 PM
MILLIGAN JOHN FPresident and COONov 09Sale107.66100,00010,765,6441,029,108Nov 12 01:01 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000033,724Nov 09 05:41 PM
MARTIN JOHN CChairman and CEONov 02Option Exercise14.50150,0002,175,3754,098,066Nov 04 01:23 PM
Alton Gregg HEVP, Corp & Med AffairsNov 02Option Exercise24.3010,000242,950143,422Nov 04 02:41 PM
Carter Paul RutherfordEVP Commercial OpsNov 02Sale108.362,000216,71248,783Nov 04 04:27 PM
Washington Robin LEVP, CFONov 02Sale109.466,250684,15088,046Nov 04 04:21 PM
Alton Gregg HEVP, Corp & Med AffairsNov 02Sale109.3812,0001,312,507131,422Nov 04 02:41 PM
MARTIN JOHN CChairman and CEONov 02Sale109.42150,00016,413,0263,948,066Nov 04 01:23 PM
Cogan John FrancisDirectorOct 27Option Exercise20.7115,000310,57559,309Oct 28 08:13 PM
Cogan John FrancisDirectorOct 27Sale110.0015,0001,650,00044,309Oct 28 08:13 PM
Cogan John FrancisDirectorOct 26Option Exercise20.7115,000310,57559,309Oct 27 03:09 PM
Cogan John FrancisDirectorOct 26Sale110.0015,0001,650,00044,309Oct 27 03:09 PM
Carter Paul RutherfordEVP Commercial OpsOct 26Sale110.061,500165,09248,783Oct 28 02:51 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 15Option Exercise23.6070,0001,652,248235,168Oct 16 05:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 15Sale100.0570,0007,003,220165,168Oct 16 05:32 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise14.50100,0001,450,2501,129,108Oct 08 02:06 PM
MILLIGAN JOHN FPresident and COOOct 07Sale99.22100,0009,921,5241,029,108Oct 08 02:06 PM
Alton Gregg HEVP, Corp & Med AffairsOct 05Option Exercise24.305,000121,475138,422Oct 07 01:22 PM
Alton Gregg HEVP, Corp & Med AffairsOct 05Sale100.005,000500,000133,422Oct 07 01:22 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise14.50150,0002,175,3754,098,066Oct 05 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise24.305,000121,475140,422Oct 05 02:13 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale97.287,000680,930133,422Oct 05 02:13 PM
MARTIN JOHN CChairman and CEOOct 01Sale97.48150,00014,622,2893,948,066Oct 05 01:28 PM
Carter Paul RutherfordEVP Commercial OpsOct 01Sale98.592,000197,18048,783Oct 05 04:26 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 15Option Exercise23.6070,0001,652,000235,168Sep 17 04:26 PM
Cogan John FrancisDirectorSep 15Option Exercise20.7115,000310,57559,309Sep 17 03:54 PM
Alton Gregg HEVP, Corp & Med AffairsSep 15Option Exercise24.305,000121,475140,422Sep 17 03:55 PM
Alton Gregg HEVP, Corp & Med AffairsSep 15Sale110.005,000550,000135,422Sep 17 03:55 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 15Sale110.7070,0007,749,195165,168Sep 17 04:26 PM